Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Danny Rischin, MD, on Cemiplimab for Metastatic Squamous Cell Carcinoma

Posted: Tuesday, July 10, 2018

Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase II study findings on cemiplimab, a human monoclonal anti–PD-1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.